Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo with best supportive care in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Yoshino says that TAS-102 is well tolerated overall with very mild toxicity. The most common adverse events observed in the TAS-102 arm were hematologic, including anemia (16.5%) and neutropenia (34.9%).

There were also some incidences of diarrhea, pyrexia and vomiting, Yoshino says, but these were generally manageable. Based on this, Yoshino says he believes that TAS-102 is very well tolerated in almost all patients.

View more from the 2014 World GI Congress

Videos

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Dr. Yoshino Discusses the Safety Profile of TAS-102

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.

Yoshino presented results of a phase I study of U3-1565 at the 2013 European Cancer Conference. U3-1565 is a fully human anti-HB-EGF monoclonal antibody that targets the solid tumor, Yoshino says. The agent showed an excellent safety profile and some types of cancers showed tumor response.

Information about TAS-102, an anti-cancer drug for colorectal cancer that originated in Japan, was also presented at the conference. Yoshino says TAS-102 is an oral, nucleoside anti-tumor agent that consists of trifluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI) that prevents degradation of FTD.

View more from the 2013 European Cancer Congress

Takayuki Yoshino, MD

Articles

Dr. Yoshino Discusses the Safety Profile of TAS-102

Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer